您当前的位置：

Valsartan

(Synonyms: 缬沙坦; CGP 48933)

目录号: PL14769 纯度: ≥99%

Valsarta (CGP 48933) 是血管紧张素 II (angiotensin II) 受体拮抗剂，有潜力用于高血压和心力衰竭的研究。

CAS No. :137862-53-4

商品编号	规格	价格	会员价
PL14769-10mg	10mg	¥392.00	请登录
PL14769-50mg	50mg	¥1315.00	请登录
PL14769-100mg	100mg	¥1985.00	请登录
PL14769-200mg	200mg	¥2965.00	请登录
PL14769-500mg	500mg	询价	询价
PL14769-1 mL x 10 mM (in DMSO)	1 mL x 10 mM (in DMSO)	¥241.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Valsartan
中文别名	缬沙坦;N-(1-戊酰基)-N-[4-[2-(1H-四氮唑-5-基)苯基]苄基]-L-缬氨酸;盐酸氨溴索杂质D;CGP一48933:DIOVAN;N-(1-氧戊基)-N-[[2'(-(1H-四唑-5-基)[1,1'(-联苯]-4-基]甲基]-L-缬氨酸;颉沙坦;缬沙坦 EP标准品;缬沙坦 USP标准品;缬沙坦标准品;缬沙坦标准品(JP);缬沙坦峰鉴别 EP标准品;缬沙坦系统适应性 EP标准品;缬沙坦杂质;辛伐司他汀;N-戊酰基-N-[2'-(1H-四唑-5-基)联苯-4-基甲基]-L-缬氨酸
英文名称	Valsartan
英文别名	Valsartan;CGP-48933;VALSARTAN, MM STANDARD;VALSARTAN, USP STANDARD;VALSARTAN, RELATED COMPOUND A(R)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE USP STANDARD;VALSARTAN, RELATED COMPOUND C(S)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE BENZYL ESTER USP STANDARD;N-[[(2-Cyano(1.1-Biphenyl)-4-Yl)Methyl]MethylEster]-L-Valine.Hydrochloride;ValsartanC24H29N503;Diovan, N-(1-Oxopentyl)-N-[[2(1H-tetrazol-5-yl)[1,1biphenyl]-4-yl]methyl]-L-valine, CGP-48933;L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI);Nisis;Tareg;(S)-2-(N-((2''-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID;N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine;(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid;CGP 48933;GMP;L-Valsartan;N-(1-N.PENTANOYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1'',1- BIPHENYL]-4-YL]METHYL]-L-VALINE;N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine;Valsartan API;Valsartane;Valsratan;N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine;3-Methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid;N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine;Diovan;[ "" ];Provas;Exforge;N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine;80M03YXJ7I;C24H29N5O3;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid;Kalpres;Valsarta
Cas No.	137862-53-4
分子式	C₂₄H₂₉N₅O₃
分子量	435.52
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	Valsarta (CGP 48933) 是血管紧张素 II (angiotensin II) 受体拮抗剂，有潜力用于高血压和心力衰竭的研究。

产品详情

Valsarta (CGP 48933) 是血管紧张素 II (angiotensin II) 受体拮抗剂，有潜力用于高血压和心力衰竭的研究。

生物活性

Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.

性状

Solid

体外研究(In Vitro)

Valsartan (CGP 48933) is a synthetic non-peptide angiotensin II type 1 receptor antagonist that dilates blood vessels and reduces blood pressure by blocking the action of angiotensin. Valsartan significantly decreases the expression of AT1R in ageing aorta endothelial cells.
The pretreatment of valsartan results in an inhibition of TLR2 signaling and proinflammatory cytokines. The expression of AGTR1 is up-regulated after alcohol exposure, and is blocked by valsartan pretreatment. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Valsartan (CGP 48933) significantly attenuates the expression of TGF-β/Smad, Hif-1α and fibrosis-related protein in rats after MI. Heart function, infarcted size, wall thickness as well as myocardial vascularization of ischaemic hearts are also significantly improved by valsartan compared with saline and hydralazine.
Valsartan partially reverses the effects of high-salt diet on hypertension, cardiac injuries such as fibrosis and inflammatory cell infiltration, and inhibition of aquaporin 1 and angiogenic factors; valsartan alone does not exert such effects.
Valsartan is an effective antidepressant/antianxiety reagent and can promote the hippocampal neurogenesis and expression of BDNF. Chronic administration of valsartan (5-40 mg/kg/d, p.o.) increases the time spent in the center of the field in OFT and the latency to eat in NSF, reduces the immobility time in both

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Shan H, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014 Jun;18(6):1071-80.
[2]. Wang Y, et al. Valsartan blocked alcohol-induced, Toll-like receptor 2 signaling-mediated inflammation in human vascular endothelial cells. Alcohol Clin Exp Res. 2014 Oct;38(10):2529-40.

溶解度数据	In Vitro: DMSO : 50 mg/mL (114.81 mM; Need ultrasonic)H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Valsartan

相关产品

The molarity calculator equation

The dilution calculator equation